Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 13/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832992 | 0.92 | SLC16A3 (0.48) | SLC16A3KDRPDGFRBMAPTMAPK1 | |
| SCHEMBL834071 | 0.91 | KDR (0.46) | SLC16A3KDRPDGFRBFFAR1 | |
| SCHEMBL833919 | 0.91 | KDR (0.54) | SLC16A3KDRPDGFRBFFAR1 | |
| SCHEMBL834505 | 0.91 | KDR (0.44) | SLC16A3KDRPDGFRBFFAR1 | |
| SCHEMBL835768 | 0.90 | KDR (0.52) | SLC16A3KDRPDGFRBMAPTMAPK1 | |
| SCHEMBL834022 | 0.90 | KDR (0.44) | KDRPDGFRBFFAR1 | |
| SCHEMBL836518 | 0.90 | SLC16A3 (0.45) | SLC16A3KDRPDGFRBMAPTMAPK1 | |
| SCHEMBL835659 | 0.90 | SLC16A3 (0.45) | SLC16A3KDRPDGFRBMAPTMAPK1 | |
| SCHEMBL833934 | 0.90 | KDR (0.47) | SLC16A3KDRPDGFRBMAPTMAPK1 | |
| SCHEMBL1477070 | 0.89 | KDR (0.48) | SLC16A3KDRPDGFRBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099757-B1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | SLC16A3 4324/4885KDR 51/4885PDGFRB 368/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | SLC16A3 4324/4885KDR 51/4885PDGFRB 368/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | SLC16A3 4324/4885KDR 51/4885PDGFRB 368/4885 |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | SLC16A3 4434/4885KDR 321/4885PDGFRB 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.